NRP1 and breast carcinoma: The binding peptide TLTYTWS reduces angiogenesis in lung cancer models, and TM peptide inhibits tumor growth, angiogenesis, and migration in breast cancer by targeting neuropilin-1 (NRP1) receptors [112].